Adicet Bio Announces Safety And Efficacy Data From Phase 1 Study Evaluating Prulacabtagene Leucel In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis; Prula-Cel Generally Well Tolerated With No CRS Greater Than Grade 2 And No IEC-HS Or ICANS

-At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR-

-All patients discontinued immunosuppressants –

- All but one patient tapered background steroids to ≤5 mg prednisone equivalent per day-

-Rapid reductions in SLEDAI-2K and PGA scores, consistent with autologous alpha beta CAR-T cell therapies-

-Plan to initiate pivotal lupus nephritis trial start-up activities in 4Q/2026; high DORIS remission rate may support expansion of pivotal study to include lupus without nephritis based on regulatory precedent-

-Company to host investor webcast at 8:00am ET today-